Syros Pharmaceuticals Inc. (NASDAQ:SYRS) went up by 6.39% during the previous trading session, and it is maintaining the win ahead of Thursday’s trading session. The share price of the Biotechnology giant went up by $12.15 to trade ended Thursday trading at $11.42. This is up from the $11.42 price recorded on Wednesday’s trading session. Thanks to this latest performance, SYRS is closer to the higher price 52-week target of $17.00 and further from the lowest price target of $8.00. Its performance from the start of the year has also been positive, with SYRS up by 75.83% year-to-date.
Syros Pharmaceuticals Inc. (SYRS) started the day trading at $11.6 and recorded an intraday high of $12.36. It also recorded an intraday low of $10.74 during Thursday’s trading session. Syros Pharmaceuticals Inc. is a very active stock that recorded a trading volume that is less than -24.6% of the average daily trading volume on Thursday. The stock’s trading volume on Thursday was 300890, which is less than -24.6 of the total average daily trading volume of 374.90K.
Syros Pharmaceuticals Inc. (NASDAQ:SYRS) 2020 Performance Impressive
The increase in SYRS’s stock price on Thursday saw its overall performance boost over the past few months. We can quantify the performance of the stock so far this year using a few metrics. The 52-week high price of SYRS currently stands at $11.93, which is lower than the current trading price of the stock by -1.84%. However, SYRS’s current trading price is -185.21% lower than the 52-week low price of $4.26. In terms of trading volume, Syros Pharmaceuticals Inc. currently experienced healthy participation during the last trading session. 300890 shares of Syros Pharmaceuticals Inc. were traded on the stock exchange on Thursday, which is less than -24.6% of the 374.90K average trading volume of the stock.
The performance of the stock has been positive over the past year. SYRS’s performance over the past one year has seen it surge by 42.77%, while the stock has gone up by 70.41% in the last six months. The quarterly performance of SYRS currently stands at 111.67%, and it is up by 28.30% in the last month. The only positive figure was from the weekly performance, which currently reads 10.15%. At the time of writing SYRS’s report, the company has a total market cap of $521.84M, making it one of the largest publicly-traded companies in the world.Syros Pharmaceuticals Inc. also has over 83 employees all over the world.
SYRS Insider Activities
For Syros Pharmaceuticals Inc., insiders hold 88.80% of all company shares. The insider transactions over the past six months are down by -123.50%. During that period, insiders bought 10,000 shares in 1 transactions. In that same period, insiders sold 192,086 of their shares in 7 transactions. After these transactions, insiders at Syros Pharmaceuticals Inc. now hold 4.14M shares, which is over 86.76% of the total company stocks. Institutional investors currently hold a large chunk of the SYRS shares, as they control 9.05% of the company’s total stock.
SYRS Fundamental Analysis
For Syros Pharmaceuticals Inc., the stock’s diluted earnings per share (EPS) stands at -1.79. In the coming year, analysts expect the EPS to be -1.64. The stock’s EPS growth this year is 1.70%, -22.20% in the previous five years. In terms of revenue, Syros Pharmaceuticals Inc.’s quarterly sales (YOY) is shrinking at -0.40, which is higher than the average annual revenue of -22.20% over the past half a decade.
The Return on Investment (ROI) on Syros Pharmaceuticals Inc.’s stock currently stands at -97.20%.
SYRS Analysts Prediction
and Wedbush reiterate their Outperform position on the stock ($11 and $13).
At the moment, Syros Pharmaceuticals Inc.’s Total Debt to Equity ratio stands at 0.27, and they have a long-term Debt to Equity ratio of 0.26.
SYRS Technical Analysis
The Simple Moving Average (SMA) is one of the most powerful technical indicators. The 20-day Simple Moving Average of SYRS currently stands at 23.18%, while the SMA50 is 28.72%. The biggest one is the SMA200, which is currently reading 62.62% ahead of Thursday’s trading session. The Relative Strength Index of this stock is 69.05.
